CYTOMEDIX, INC. v. PERFUSION PARTNERS & ASSOCIATES No. 02 C 4776.
243 F.Supp.2d 786 (2003)
CYTOMEDIX, INC., Plaintiff, v. PERFUSION PARTNERS & ASSOCIATES, INC., a Florida corporation, Florida Platelet Gel Symposium, a Florida corporation, Emery Smith, David Buzenius, Patrick Pennie, and Lisa Colas Defendant.
United States District Court, N.D. Illinois, Eastern Division.
February 3, 2003.
Gordon R. Coons, Eley O. Thompson, John Lodge Gase, Leydig, Voit & Mayer, Ltd., Chicago, IL, for defendants.
MEMORANDUM OPINION AND ORDER
KENNELLY, District Judge.
Plaintiff Cytomedix has sued Perfusion Partners & Associates Inc. (PPAI), and three individually named PPAI employees,
Cytomedix is in the business of developing, licensing, and distributing "autologous cellular therapies" using medical patients' own platelets and blood components for the treatment of chronic wounds. Complaint ¶¶ 5, 13. It holds domestic and foreign patents relating to the use of a particular wound therapy composition known as "Autologel." Complaint ¶ 14. The company has recently emerged from bankruptcy. Defendant PPAI is a small healthcare provider in Florida. PPAI's Mot. to Dismiss at 1. Defendants Smith, Buzenius and Pennie are PPAI employees. Individual Defendants' Mot. to Dismiss at 1-2. The complaint alleges that PPAI and its employees have infringed upon Cytomedix's patents and have violated the Lanham Act by "making and using autologous cellular therapies and platelet gel products." Complaint ¶ 5-6.
The motions to dismiss currently before the court, however, do not concern the details of Cytomedix's claims. Rather, defendants challenge the basis of this Court's jurisdiction over the case as alleged in the complaint. Instead of asserting patent law jurisdiction over its infringement and unfair competition claims, Cytomedix has characterized its suit as an adversary proceeding "related to" its federal bankruptcy case. Complaint ¶ 3. Defendants dispute this characterization and urge the Court either to dismiss the case or to reformulate jurisdiction under the patent laws. A disinterested observer might wonder why it matters; we have jurisdiction over the case either way. The answer is simple: identification of the basis for our jurisdiction determines whether the Court has personal jurisdiction over the original defendants, who have moved to dismiss for lack of personal jurisdiction, improper venue, and failure to state a claim.
As we consider defendants' 12(b) motions, we accept as true all well-pleaded allegations of the complaint and construe all ambiguities in favor of Cytomedix. Hishon v. King & Spalding,
A. "Related To" Jurisdiction Under 28 U.S.C. §§ 157(a) and 1334(b)
Cytomedix alleges that the Court has jurisdiction over this "adversary proceeding" pursuant to 28 U.S.C. § 1334(b) as "a civil proceeding arising in or related to a case under title 11 of the United States Code." Complaint ¶ 3. In support of this assertion, Cytomedix states that "[a]t the time of filing of this Complaint," it was "a chapter 11 debtor operating as debtor-in possession under the jurisdiction of the Bankruptcy Court." Id. Defendants argue that the case is simply a patent suit, the outcome of which will have no impact
"Related to" jurisdiction exists only when the dispute "affects the amount of property available for distribution or the allocation of property among creditors." In re Xonics, Inc.,
Cytomedix's complaint does not describe a connection between the subject of its patent suit and its bankruptcy reorganization. Apart from the jurisdictional allegations we have mentioned, the complaint is devoted to asserting factual and legal bases for its infringement claims. In its brief, however, Cytomedix sets forth three reasons why "related to" bankruptcy jurisdiction is proper. First, it points out that its patent case was filed before the effective date of its reorganization plan. Because its assets did not re-vest until that effective date, Cytomedix argues, its patent case remained property of the bankruptcy estate, subject to bankruptcy jurisdiction. Cytomedix next argues that even if its patent suit was not included in the bankruptcy estate for purposes of distribution to creditors, the outcome of this case will nonetheless impact creditor recovery through its influence on the company's stock. In addition, Cytomedix cites the broad reservation of jurisdiction provided for in its reorganization plan and argues that the bankruptcy court intended to resolve any future dispute involving property of the bankruptcy estate.
First, we address the timing of the complaint. The record shows that Cytomedix's reorganization plan was confirmed on June 12, 2002 and was to take effect on July 11, 2002. See Def. PPAI's Ex D; Order of Confirmation; Pl's Ex 3; Confirmed Plan. The complaint in this case was filed on July 3, 2002. There is no question, therefore, that Cytomedix filed its complaint before its reorganization plan became effective. At the time, Cytomedix remained under bankruptcy court supervision, and its assets did not re-vest until the plan's effective date a week later. See Pl's Ex 3; Confirmed Plan at 35. But this circumstance alone is not enough to confer bankruptcy jurisdiction over the case. As defendants emphasize, the complaint was filed after the reorganization plan had been confirmed. And contrary to Cytomedix's position, plan confirmation is an important turning point for purposes of bankruptcy jurisdiction. See Pettibone Corp. v. Easley,
Cytomedix insists that the outcome of the case will affect creditor recovery, or at least could have at the time the case was filed. It points out that the patents at issue were identified during bankruptcy as its most significant assets. Further, it argues that its Disclosure Statement filed in the bankruptcy case specifically identified PPAI as a potential defendant in an infringement suit and expressly reserved its right to "pursue actions against any [p]ersons who at any time ... infringed [its] [intellectual [p]roperty [a]ssets." See Pl's Ex 4 at 13-14, Appendix F. But Cytomedix neglects to mention that its patent infringement suits, including its case against PPAI, were assigned no value in its liquidation analysis and were not calculated as part of its assets for distribution in bankruptcy. See Defs Ex J; 6-7-02 Conf. Hearing at 154:7-15. As Cytomedix acknowledged during its bankruptcy proceedings, it will retain the total amount of any damages awarded in this case. See Def's Ex J; 6-6-02 Conf. Hearing at 87:11-20. Under the company's confirmed reorganization plan, its creditors have no claim on the proceeds of potential patent infringement actions. See Pl's Ex. 3 at 29. Funding for the plan comes exclusively from the funds of the bankruptcy estate, income generated by operation of the reorganized debtor's business, and fresh capital raised through a private placement offering. See id. Thus, we disagree with Cytomedix that this patent case will affect the implementation of its reorganization plan. The outcome of the case will have no impact on the distribution of the estate or the allocation of property among creditors.
We also reject Cytomedix's contention that its success or failure in the case will affect creditor recovery through the impact such results might have on shares of stock that creditors received during reorganization. The adjudication of this case may have many indirect effects, including the influence on stock value that Cytomedix proposes. But the Seventh Circuit has construed "related to" jurisdiction narrowly, rejecting litigants' efforts to obtain bankruptcy jurisdiction over controversies that do not directly concern the amount of property available for distribution. See, e.g., In re FedPak Systems, Inc.,
Cytomedix points out that in confirming its reorganization plan, the bankruptcy court reserved jurisdiction over disputes involving property of the estate. See Pl's Ex 3 at 40-42. It relies heavily on the bankruptcy court's decision to exercise that jurisdiction in a similar infringement action filed against defendant PPAI's customer, LB Hyperbarics. See Pl's Ex A; Transcript of Proceedings before Judge Wedoff. But a bankruptcy court's power to reserve jurisdiction over controversies involving the debtor or the property of the bankruptcy estate is no broader than its power to exercise "related to" jurisdiction under 28 U.S.C. § 157(a). See Zerand-Bernal Group, Inc., 23 F.3d at 163-64. In the Hyperbarics case, the bankruptcy court decided that "related to" jurisdiction was appropriate. See Pl's Ex A at 10-11. As our analysis indicates, we disagree. This is a patent infringement case wholly unrelated to Cytomedix's bankruptcy. The only interests at stake are those of the reorganized debtor and the defendants, none of which have a claim against the bankruptcy estate. The Court will retain jurisdiction over the case as an action arising under the patent laws, pursuant to 28 U.S.C. §§ 1338(a).
B. Individual Defendants' Motions
1. Personal Jurisdiction and Venue
The individual defendants have moved to dismiss based on lack of personal jurisdiction and improper venue. They argue that they live in Florida, the allegedly infringing activity took place in Florida, and they have no personal or economic contacts with Illinois. It is Cytomedix's burden to establish personal jurisdiction. Saylor v. Dyniewski,
2. Failure to State a Claim
The individual defendants also move to dismiss the patent infringement allegations against them for failure to state a claim. Because personal jurisdiction is lacking, this motion is denied as moot.
For the reasons stated above, the Court grants PPAI's motion to reformulate jurisdiction [docket item 7-1] and individual defendants Smith, Buzenius and Pennie's motion to dismiss for lack of personal jurisdiction [docket item 8-1]. The motions are otherwise denied. Florida Platelet Gel Symposium's motion to dismiss [9-1] is
- No Cases Found